ESR1 and breast carcinoma: Although trastuzumab treatment did not produce additional survival and growth inhibitory effects on AMPC-treated trastuzumab resistant cells, it was observed that trastuzumab and AMPC act synergistically to decrease the CSC-like population in the trastuzumab resistant HER2+/ER+ breast cancer cells.